Developing and innovating together
188
Results-
Business DevelopmentCreated on : - Last modified on :
-
Press ReleaseY-Biologics and Pierre Fabre confirms their research collaboration for the development of new immunotherapies in oncologyCreated on : - Last modified on :Daejeon (South Korea), Castres (France), March 29th, 2021 – The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre announce the conclusion of a strategic Research Collaboration & Optional License Agreement concerning several targets in the field of immuno-oncology.
-
Press Release1962-2022: THE PIERRE FABRE GROUP CELEBRATES ITS 60TH ANNIVERSARYCreated on : - Last modified on :Castres, May 23, 2022 - Founded on May 30, 1962 in Castres by a young pharmacist, an entrepreneur at heart and a botany enthusiast, the Pierre Fabre Group is preparing to celebrate its 60th anniversary. For six decades, without ever denying its Occitan roots, Pierre Fabre has become a world-class player in oncology, dermatology and dermo-cosmetics.
-
Press ReleasePierre Fabre becomes the first international manufacturing group to be awarded the “Outstanding” level of the Responsibility Europe label delivered by AFNOR CertificationCreated on : - Last modified on :Castres, September 28, 2022. The Pierre Fabre Group’s social and environmental responsibility policy has just been awarded the “Outstanding” level of the Responsibility Europe label from independent certification body AFNOR Certification. Pierre Fabre’s overall score of 788 points out of 1,000 means that the Group belongs to the top 1% of the 266 companies audited to-date by AFNOR Certification. It becomes the first international manufacturing group with more than 5,000 employees to obtain the “Outstanding” level of the label.
-
Our GovernanceCreated on : - Last modified on :
-
Our Key FiguresCreated on : - Last modified on :
-
Press ReleaseRARE DISEASE DAY – February 28th, 2023Created on : - Last modified on :Pierre Fabre pursues its commitment against rare diseases in the pediatric, oncology and dermatology fields. The diseases are rare, but they impact a lot of people : nearly 300 million people are affected worldwide1.
-
Press ReleaseMarie-Andrée GAMACHE joins Pierre Fabre Laboratories as CEO of the Medical CareCreated on : - Last modified on :Castres (France), March 31, 2025 – Pierre Fabre Laboratories has announced the appointment of Marie-Andrée Gamache as Chief Executive Officer (CEO) of its Medical Care. In this capacity, Marie-Andrée Gamache joins the Group’s Executive Committee and reports to Eric Ducournau, Group CEO.
-
News2023 Annual Report: Taking care of you helps us advanceCreated on : - Last modified on :In 2023, we have chosen to tell you a shared story through our annual report: that of a Group convinced that “Taking care of you helps us advance,” and which places this conviction at the heart of its action.
-
NewsMelanoma Awareness Month – We Have Your BackCreated on : - Last modified on :Malignant melanoma is a type of skin cancer that starts and develops in cells known as melanocytes – these cells are found in the upper layer of the skin and produce a pigment called melanin, giving skin its colouri. Melanoma, although less common than other skin cancers, is more dangerous because it grows and spreads quickly to other parts of the body if undetected and not treated early.i ii,
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.